Discover
RANI
Rani Therapeutics Holdings, Inc.
0.77
2 x 0.53
2 x 0.98
bid
ask
+
0.01
1.05%
2 @ 04:00 PM
0.77 +0.00 (0.21%)
| Ytd | -43.08% | |
| 1y | 49.49% |
0.75
day range
0.78
0.39
52 week range
3.87
| Open | 0.77 | Prev Close | 0.76 | Low | 0.75 | High | 0.78 | Mkt Cap | 105.64M |
| Vol | 471.43K | Avg Vol | 891.01K | EPS | -0.27 | P/E | N/A | Forward P/E | -1.41 |
| Beta | 0.11 | Short Ratio | 0.36 | Inst. Own | 19.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.89 | 200-d Avg | 1.18 | 1yr Est | 11.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.22 | -0.24 | -0.02 | -9.09% |
| 2024-08-06 | 2024-06 | -0.29 | N/A | N/A | N/A |
| 2024-08-06 | 2024-06 | -0.29 | -0.26 | 0.03 | 10.34% |
| 2024-05-06 | 2024-03 | -0.23 | N/A | N/A | N/A |
| 2024-05-06 | 2024-03 | -0.23 | -0.29 | -0.06 | -26.09% |
| 2024-03-20 | 2023-12 | -0.31 | -0.27 | 0.04 | 12.90% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-02 | Oppenheimer | Upgrade | Outperform | |
| 2024-06-25 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-14 | Maxim Group | Upgrade | Buy |
Profile
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-11-16 | BUTEL JEAN LUC | Director | 50.50K | Purchase |
| 2023-03-26 | GROEN ERIC | General Counsel | 163.22K | Stock Award(Grant) |
| 2023-03-26 | HASHIM MIR | Officer | 273.27K | Stock Award(Grant) |
| 2024-12-08 | IMRAN TALAT | Chief Executive Officer | 494.75K | Purchase |
| 2024-12-12 | MCKINLEY KATE | Officer | 17.96K | Purchase |
| 2023-11-15 | NANAVATY MAULIK | Director | 11.52K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Armistice Capital, LLC | 2.57M | 3.66M | 7.73% |
| 2024-09-29 | Vanguard Group Inc | 709.83K | 1.01M | 2.13% |
| 2024-09-29 | Nan Fung Group Holdings Limited | 493.58K | 700.89K | 1.48% |
| 2024-09-29 | Alphabet Inc. | 448.49K | 636.86K | 1.35% |
| 2024-09-29 | United Services Automobile Association | 302.74K | 429.90K | 0.91% |
| 2024-09-29 | Stifel Financial Corporation | 269.77K | 383.07K | 0.81% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 518.70K | 736.56K | 1.56% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 172.98K | 245.63K | 0.52% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 88.84K | 126.16K | 0.27% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 71.50K | 101.53K | 0.21% |
| 2024-10-30 | Fidelity Total Market Index Fund | 26.17K | 37.16K | 0.08% |
| 2024-09-29 | Northern Small Cap Core Fund | 23.70K | 33.65K | 0.07% |